Trial reportAnnals of family medicine
Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Trial report in Annals of family medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 118 citations in OpenAlex.
- Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2015Trial
- A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.Drug and alcohol dependence · 2015Trial
- Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.Addictive behaviors · 2012Trial
- Comparison of buprenorphine treatment for opioid dependence in 3 settings.Journal of addiction medicine · 2012Trial
- Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons.Journal of substance abuse treatment · 2010Trial
- Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.Addictive behaviors · 2010Trial
- Modeling Recurrent Events: A Tutorial Based on Relapse and Remitting Episodes during Medication-Assisted Treatment for Opioid Use Disorder.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.Journal of substance use and addiction treatment · 2024Article
- Predicting premature discontinuation of medication for opioid use disorder from electronic medical records.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2023Article
- Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.Nature and science of sleep · 2023Article
- Nudging primary care providers to expand the opioid use disorder workforce.Health services research · 2022Article
- Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.Journal of substance abuse treatment · 2021Article
- The "black box" of treatment: Patients' perspective on what works in opioid maintenance treatment for opioid dependence.Substance abuse treatment, prevention, and policy · 2021Article
- Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.Annals of family medicine · 2020Article
- Article
- Implementing group visits for opioid use disorder: A case series.Substance abuse · 2020Article
- Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice.Addiction science & clinical practice · 2019Article
- Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review.Systematic reviews · 2019Article
- Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.The Journal of clinical psychiatry · 2019Article
- Predictors of buprenorphine treatment success of opioid dependence in two Baltimore City grassroots recovery programs.Addictive behaviors · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOffice-based treatment of opioid addiction with a combination of buprenorphine and naloxone was approved in 2002. Efficacy of this treatment in non-research clinical settings has not been studied. We examined the efficacy and practicality of buprenorphine-naloxone treatment in primary care settings.
methodsWe studied a cohort of 99 consecutive patients enrolled in buprenorphine-naloxone treatment for opioid dependence at 2 urban primary care practices: a hospital-based primary care clinic, and a primary care practice in a free-standing neighborhood health center. The primary outcome measure was sobriety at 6 months as judged by the treating physician based on periodic urine drug tests, as well as frequent physical examinations and questioning of the patients about substance use.
resultsFifty-four percent of patients were sober at 6 months. There was no significant correlation between sobriety and site of care, drug of choice, neighborhood poverty level, or dose of buprenorphine-naloxone. Sobriety was correlated with private insurance status, older age, length of treatment, and attending self-help meetings.
conclusionsOpioid-addicted patients can be safely and effectively treated in non-research primary care settings with limited on-site resources. Our findings suggest that greater numbers of patients should have access to buprenorphine-naloxone treatment in nonspecialized settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.